Synergistic Inhibition of Survival, Proliferation, and Migration of U87 Cells with a Combination of LY341495 and Iressa

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yelskaya, Zarina ^a   Carrillo, Vangie ^a   Dubisz, Ewa ^a   Gulzar, Hira ^a   Morgan, Devon ^a   Mahajan, Shahana S ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMPA RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUTAMIC ACID; METABOTROPIC RECEPTOR 2; RILUZOLE; AMINO ACID; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; XANTHENE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MONOTHERAPY; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN TARGETING; TREATMENT OUTCOME; TUMOR GROWTH; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOBLASTOMA; GLUTAMIC ACID; HUMANS; QUINAZOLINES; RILUZOLE; XANTHENES;

EID: 84878306173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064588     Document Type: Article

References (54)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333.
2. Kleihues P, Sobin LH, (2000) World Health Organization classification of tumors. Cancer 88: 2887.
3. Laerum OD, Bjerkvig R, Steinsvag SK, de Ridder L, (1984) Invasiveness of primary brain tumors. Cancer Metastasis Rev 3: 223-236.
4. Gupta T, Sarin R, (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3: 557-564.
5. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M, (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31: 300-305.
6. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J, (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47: 11-22.
7. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, et al. (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7: 1010-1015.
8. Ye ZC, Rothstein JD, Sontheimer H, (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19: 10767-10777.
9. Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, et al. (2005) Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7: 236-245.
10. Noch E, Khalili K, (2009) Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 8: 1791-1797.
11. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H, (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67: 9463-9471.
12. Sontheimer H, (2003) Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26: 543-549.
13. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, et al. (2002) Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8: 971-978.
14. Geiger JR, Melcher T, Koh DS, Sakmann B, Seeburg PH, et al. (1995) Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 15: 193-204.
15. Melcher T, Maas S, Higuchi M, Keller W, Seeburg PH, (1995) Editing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA in vitro reveals site-selective adenosine to inosine conversion. J Biol Chem 270: 8566-8570.
16. de Groot JF, Liu TJ, Fuller G, Yung WK, (2005) The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65: 1934-1940.
17. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, et al. (2007) Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27: 7987-8001.
18. Rzeski W, Turski L, Ikonomidou C, (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 98: 6372-6377.
19. van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ, Postma TJ, et al. (2009) Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS One 4: e5953.
20. Mahajan SS, Ziff EB, (2007) Novel toxicity of the unedited GluR2 AMPA receptor subunit dependent on surface trafficking and increased Ca2+-permeability. Mol Cell Neurosci 35: 470-481.
21. Mahajan SS, Thai KH, Chen K, Ziff E, (2011) Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing. Neuroscience 189: 305-315.
22. Yoshida Y, Tsuzuki K, Ishiuchi S, Ozawa S, (2006) Serum-dependence of AMPA receptor-mediated proliferation in glioma cells. Pathol Int 56: 262-271.
23. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, et al. (2001) Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678.
24. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
25. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, et al. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 279: 710-714.
26. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, et al. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 277: 567-570.
27. Vanhaesebroeck B, Alessi DR, (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 3: 561-576.
28. Toker A, Newton AC, (2000) Cellular signaling: pivoting around PDK-1. Cell 103: 185-188.
29. Toker A, Newton AC, (2000) Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275: 8271-8274.
30. Schunemann DP, Grivicich I, Regner A, Leal LF, de Araujo DR, et al. (2010) Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line. Pathol Oncol Res 16: 285-293.
31. Hoi Sang U, Espiritu OD, Kelley PY, Klauber MR, Hatton JD, (1995) The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 82: 841-846.
32. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970.
33. Maehama T, Dixon JE, (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
34. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
35. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. (2003) Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746.
36. Ghosh MK, Sharma P, Harbor PC, Rahaman SO, Haque SJ, (2005) PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells. Oncogene 24: 7290-7300.
37. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, et al. (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
38. Decraene D, Van Laethem A, Agostinis P, De Peuter L, Degreef H, et al. (2004) AKT status controls susceptibility of malignant keratinocytes to the early-activated and UVB-induced apoptotic pathway. J Invest Dermatol 123: 207-212.
39. McLendon RE, Turner K, Perkinson K, Rich J, (2007) Second messenger systems in human gliomas. Arch Pathol Lab Med 131: 1585-1590.
40. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR, (1998) In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 153: 1411-1423.
41. Cuevas P, Diaz-Gonzalez D, Garcia-Martin-Cordova C, Sanchez I, Lozano RM, et al. (2006) Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cells. J Cell Mol Med 10: 225-230.
42. D'Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, et al. (2003) Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 84: 1288-1295.
43. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, et al. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404: 15-21.
44. Goldberg L, Kloog Y, (2006) A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66: 11709-11717.
45. Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T, (2008) Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 578: 171-176.
46. Akamatsu K, Shibata MA, Ito Y, Sohma Y, Azuma H, et al. (2009) Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress. Anticancer Res 29: 2195-2204.
47. Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, et al. (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132: 565-573.
48. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, et al. (2009) The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci 30: 25-34.
49. Maas S, Patt S, Schrey M, Rich A, (2001) Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A 98: 14687-14692.
50. Xue D, Huang ZG, Barnes K, Lesiuk HJ, Smith KE, et al. (1994) Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J Cereb Blood Flow Metab 14: 251-261.
51. El-Kholy W, Macdonald PE, Lin JH, Wang J, Fox JM, et al. (2003) The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J 17: 720-722.
52. Nauc V, De Lamirande E, Leclerc P, Gagnon C, (2004) Inhibitors of phosphoinositide 3-kinase, LY294002 and wortmannin, affect sperm capacitation and associated phosphorylation of proteins differently: Ca2+-dependent divergences. J Androl 25: 573-585.
53. Tsai KD, Chang WW, Lin CC, Hsu SC, Lee YJ, et al. (2012) Differential effects of LY294002 and wortmannin on inducible nitric oxide synthase expression in glomerular mesangial cells. Int Immunopharmacol 12: 471-480.
54. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, et al. (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4: 641-649.